Thus, therapeutic approaches targeting the JAK/STAT3 pathway may benefit cancer patients, not only through promoting tumor inhibition but also by attenuating PD-L1 expression to enhance anti-tumor immunity. This evidence concerns the gene STAT3 and neoplasm.